SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence
Background. Over the last few years, the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) has increased substantially in medical practice due to their documented benefits in cardiorenal and metabolic health. In this sense, and in addit...
Saved in:
Main Authors: | Luis D'Marco, Valery Morillo, José Luis Gorriz, María K. Suarez, Manuel Nava, Ángel Ortega, Heliana Parra, Nelson Villasmil, Joselyn Rojas-Quintero, Valmore Bermúdez |
---|---|
Format: | article |
Language: | EN |
Published: |
Hindawi Limited
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/2429d38f9c04442fa80e1693aa5bb47e |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages
by: Masao Koike, et al.
Published: (2021) -
GLP-1, SGLT-2, new devices for interventional cardiologists
by: Çetin Erol
Published: (2021) -
An updated perspective and pooled analysis of cardiovascular outcome trials of GLP-1 receptor agonists and SGLT-2 inhibitors
by: Mustafa Kılıçkap, et al.
Published: (2021) -
Estimated visceral adiposity is associated with risk of cardiometabolic conditions in a population based study
by: Maria Ruiz-Castell, et al.
Published: (2021) -
Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients
by: Kazushi Uneda, et al.
Published: (2021)